MedTrace Logo

Pain Management After Transnasal Transsphenoidal Surgery for Pituitary Adenomas

NCT04611685 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 202

Last updated 2020-11-03

No results posted yet for this study

Summary

We hypothesize that the effects of non-steroidal anti-inflammatory drugs (NSAIDS) for pain relief among patients with pituitary adenomas undergoing transnasal transsphenoidal surgeries are non-inferior to tramadol. We aim to launch a single-center randomized clinical trial to verify this hypothesis.

Conditions

  • Pituitary Adenoma
  • Surgery
  • Pain

Interventions

DRUG

NSAID

Immediately after the operation, the patient is given (parecoxib 40 mg + sodium chloride 100 ml) intravenously once, and then given (loxoprofen 60 mg) orally twice a day during the first three postoperative days.

DRUG

Tramadol

Immediately after the operation, the patient is given (tramadol 100 mg) intramuscularly once, and then given (tramcontin 100 mg) orally twice a day during the first three postoperative days.

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    lead OTHER

Principal Investigators

  • Bing Xing, MD · Neurosurgery, Peking Union Medical College Hospital, Beijing, China

  • Wei Lian, MD · Neurosurgery, Peking Union Medical College Hospital, Beijing, China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-31
Primary Completion
2021-10-31
Completion
2021-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04611685 on ClinicalTrials.gov